

many startup companies begin idea proprietary technology technology straightforward easily explained times novel revolutionary
for founders  double edged sword especially begin seek outside financing technology new  hard explain prove  potentially disruptive attract significant attention potential investors
the happened disgraced healthcare startup theranos founder elizabeth holmes raised massive rounds financing promise new way test blood transform medical testing mankind investors threw money holmes theranos leading valuation  billion  financing round
as media recently reported appear theranos investors experience medical biopharma industries ties technology industry came software backgrounds strong political players us
these investors likely did perform diligence theranos technology backgrounds possible did know look theranos known cards close chest secretive technology data
regardless investors kept coming giving money company investing doing homework technology instead relying earlier investors believed performed diligence recent op ed fortune magazine marketing professor kent grayson explained phenomenon trusting credence goods
some excuse theranos secrecy merely protecting intellectual property technology addition desiring confidentiality company having worked biotechnology industry years having raised capital medical products startup i say that argument does hold water
founders  open scrutiny diligence potential investors bringing scientists experts audit company trust analyze technology data especially medical sector confidentiality agreements protections place diligence process trust people secrets confidentiality agreement  business reason ca share data externally validated
in theranos case possible investors invested technology ultimately deliver promised unfortunately scenario does happen companies oversell technology overstating capabilities fail pursue rigorous scientific procedure respect efficacy technology investors caught narrative company theranos particular media darling wall street journal groundbreaking report year
it worth noting known investors biotechnology life sciences spaces especially silicon valley did invest theranos investors expertise experience fields knew look case biotechnology investors thought theranos technology good  true theranos continued raise money announce new applications technology remained unwilling share data red flag told savvy biotechnology investors stay away
for medical startup companies able share data (under proper confidentiality agreements having technology validated clinical trials peer reviewed medical journals  welcome good thing  able prove effectiveness product want  able investors product works valid applications
founders   open party validation took time product  medical device treatment snoring sleep apnea  undergo clinical testing peer review time took product market raised capital later data share showed product clinically proven technology scientifically sound
at time diligence responsibility investors perform diligence simply relying credibility pedigree management te risk investing products technology ultimately proven unsound
